Endocrine Abstracts

Introduction: Cross-sex hormone treatment (CHT) in male-to-female (M2F) transsexuals affects the hemostatic balance, with the emergence of a prothrombotic state with the use of certain estrogen (oral ethinyl estradiol vs 17β estradiol). Testosterone administration to F2M transsexuals had an antithrombotic effect. In female-to-male in (F2M) transsexuals administration of testosterone seems to carry a mild antithrombotic effect.

Objective: To quantify prevalence of alterations in the coagulation parameters in naive transsexuals people for CHT. To quantify changes of hemostatic variables after 12 months of physiology doses treatment: M2F (17βestradiol with cyproterone acetate/espyronolactone) and F2M (testosterone td, im).

Subjects and Methods: A prospective, observational study of 47 CHT-naive patients; available data of hemostatic balance in 15 patients (8 M2F, 7 F2M) baseline and after 12 months of treatment. Statistical analysis: descriptive statistics and prevalence; Wilcoxon test for paired data for changes in hemostatic state (SPSS 11.0 for windows).

Results: Prevalence of coagulation alterations 21%(IC95%12–35): 3 patients antiphospholipid antibody; 6 prothrombin gene G20210A mutations, 1 increased beta 2 glycoprotein. Antiplatelet treatment was initiated in two M2F (acetylsalicylic acid). Significant differences of hemostatic variables were demonstrated in M2F people on Trombin Time. There were not differences on F2M.

Conclusions: The prevalence of coagulopaties in transsexual people is moderated and similar to general population. The administration of 17βestradiol in combination with cyproterone acetate on M2F or testosterone on F2M it was not associated with changes of hemostatic balance.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.